Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar;14(3):255-64.
doi: 10.6004/jnccn.2016.0031.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016

David S Ettinger  1 , Douglas E Wood  2 , Wallace Akerley  3 , Lyudmila A Bazhenova  4 , Hossein Borghaei  5 , David Ross Camidge  6 , Richard T Cheney  7 , Lucian R Chirieac  8 , Thomas A D'Amico  9 , Thomas J Dilling  10 , M Chris Dobelbower  11 , Ramaswamy Govindan  12 , Mark Hennon  7 , Leora Horn  13 , Thierry M Jahan  14 , Ritsuko Komaki  15 , Rudy P Lackner  16 , Michael Lanuti  17 , Rogerio Lilenbaum  18 , Jules Lin  19 , Billy W Loo Jr  20 , Renato Martins  12 , Gregory A Otterson  20 , Jyoti D Patel  21 , Katherine M Pisters  15 , Karen Reckamp  22 , Gregory J Riely  23 , Steven E Schild  24 , Theresa A Shapiro  1 , Neelesh Sharma  25 , James Stevenson  25 , Scott J Swanson  8 , Kurt Tauer  26 , Stephen C Yang  1 , Kristina Gregory  27 , Miranda Hughes  27
Affiliations

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016

David S Ettinger et al. J Natl Compr Canc Netw. 2016 Mar.

Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30. - PubMed
    1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2012, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Bethesda, MD: National Cancer Institute; 2015. Available at: http://seer.cancer.gov/csr/1975_2012/. Accessed February 8, 2016.
    1. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/statfacts/html/lungb.html. Accessed February 8, 2016.
    1. Ettinger DS, Cox JD, Ginsberg RJ, et al. NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 1996;10:81–111. - PubMed
    1. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015;33:2004–2012. - PMC - PubMed

MeSH terms